Edward P. Feener - May 3, 2021 Form 4/A - Amendment Insider Report for KalVista Pharmaceuticals, Inc. (KALV)

Role
Chief Scientific Officer
Signature
/s/ Benjamin L. Palleiko, Attorney-in-Fact
Stock symbol
KALV
Transactions as of
May 3, 2021
Transactions value $
-$149,051
Form type
4/A - Amendment
Date filed
5/7/2021, 06:05 PM
Date Of Original Report
May 6, 2021
Next filing
May 28, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KALV Common Stock Sale -$149K -6K -11.06% $24.84 48.2K May 3, 2021 Direct F1, F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On May 6, 2021, the reporting person filed a Form 4 which the transaction was inadvertently reported as an exercise and sale of options for common stock of the Issuer. As reported in this amendment, the reporting person sold 6,000 shares of common stock pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
F2 The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.54 to $25.32, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.